Report: Achieving launch excellence in the challenging healthcare markets of today

Blue Latitude Health|10th December 2018

Healthcare markets are becoming more competitive and complex. The sheer number of products coming off patent in the next five years, coupled with the growing healthcare spend and the number of players entering the healthcare space, mean it's clear pharma launches are becoming more challenging.

Adding to the pressure is the evolving networks of stakeholders who each have a differing needs and pain points and often communicate using novel digital channels.

However, while the market can seem overwhelming, these challenges provide pharma organisations with an opportunity to meet the unmet needs of customers through clearer and more targeted marketing, and more streamlined launches.

This in-depth report was created in collaboration with Pharma Intelligence and is based on our significant experience in this area. It features interviews with senior leaders and primary market research, as well as giving key recommendations for achieving launch success in challenging markets.

Download the white paper to learn:

  • The characteristics of launch excellence evidenced by successful launches from the last two years
  • How to transform the operating model to ensure market responsiveness
  • How you can re-focus your brand planning to maximise success.

Launch Excellence 2020

Blue Latitude Health|18th November 2019

In this publication, we explore what makes a successful pharma launch from developing insight that drives behaviour change to lean launches and multi-indication launches, as well as an evaluation of the CAR-T market.

read more

Precision medicine at Blue Latitude Health

Blue Latitude Health|7th November 2019

At Blue Latitude Health we have identified 90+ insights about commercialising precision medicines. Check out our video to get a run down on three core components of the commercialisation and launch of precision medicines.

read more

Understanding the evolving CAR-T market

Ditte Funding, Maria Katsarou, Natasha Cowan|1st November 2019

In 2017 the approval of the first CAR-T treatment took the world by storm, transforming the way cancer is treated, but two years later more than 500 CAR-Ts are in development. So how can pharma ensure its product stands out from the crowd?

read more